|

Brelovitug 300 mg Clinical Trials

2 actively recruiting trials across 1 location

Also known as: BJT-778, BTG

Pipeline

Phase 3: 2

Top Sponsors

  • Mirum Pharmaceuticals, Inc.2

Indications

  • Liver Disease2
  • Chronic Hepatitis D Infection2

Other1 trial

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Phase 3

Davis, California1 trial

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

University of California, Davis

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.